Under the terms of the agreement, NovaScreen will use Caliper's LabChip 3000 microfluidic screening platform to screen 500,000 compounds against an inflammatory target.
According to NovaScreen, the LabChip 3000 technology helps eliminate false positives in the primary screen.
Financial details of the agreement were not disclosed.
Caliper purchased NovaScreen for approximately $30 million last October.